Whilst endogenous EPO levels have been shown to predict survival in this cohort, it remains to be studied whether EPO is also a useful marker for monitoring, follow-up and clinical management of patients with severe aortic stenosis after TAVR, as has been observed in a few studies in patients with heart failure (8). The gene discussed is EPO; the disease is heart failure.